DE69825473D1 - Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine - Google Patents

Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine

Info

Publication number
DE69825473D1
DE69825473D1 DE69825473T DE69825473T DE69825473D1 DE 69825473 D1 DE69825473 D1 DE 69825473D1 DE 69825473 T DE69825473 T DE 69825473T DE 69825473 T DE69825473 T DE 69825473T DE 69825473 D1 DE69825473 D1 DE 69825473D1
Authority
DE
Germany
Prior art keywords
blockadetherapy
inhibitation
syndrome
therapeutic proteins
exogenous protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69825473T
Other languages
English (en)
Other versions
DE69825473T2 (de
Inventor
Burt Adelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of DE69825473D1 publication Critical patent/DE69825473D1/de
Application granted granted Critical
Publication of DE69825473T2 publication Critical patent/DE69825473T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69825473T 1997-06-20 1998-06-19 Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine Expired - Fee Related DE69825473T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
US50276P 1997-06-20
PCT/US1998/012773 WO1998058672A1 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Publications (2)

Publication Number Publication Date
DE69825473D1 true DE69825473D1 (de) 2004-09-09
DE69825473T2 DE69825473T2 (de) 2005-08-04

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69825473T Expired - Fee Related DE69825473T2 (de) 1997-06-20 1998-06-19 Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine

Country Status (25)

Country Link
US (1) US20020119151A1 (de)
EP (1) EP1034001B1 (de)
JP (1) JP2002504910A (de)
KR (1) KR100567998B1 (de)
CN (2) CN1651071A (de)
AT (1) ATE272408T1 (de)
AU (1) AU733062B2 (de)
BG (1) BG64436B1 (de)
BR (1) BR9810755A (de)
CA (1) CA2294138A1 (de)
CZ (1) CZ295805B6 (de)
DE (1) DE69825473T2 (de)
EA (1) EA002512B1 (de)
EE (1) EE9900587A (de)
ES (1) ES2226152T3 (de)
HK (1) HK1031825A1 (de)
HU (1) HUP0002048A3 (de)
IL (1) IL133305A0 (de)
IS (1) IS2097B (de)
NO (1) NO996274L (de)
NZ (1) NZ502051A (de)
PT (1) PT1034001E (de)
SK (1) SK285962B6 (de)
TR (1) TR199903141T2 (de)
WO (1) WO1998058672A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2343916A1 (en) * 1998-09-21 2000-03-30 Genetics Institute, Inc. Methods of downmodulating the immune response to therapeutic proteins
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CN1441675A (zh) 2000-05-12 2003-09-10 贝斯以色列护理医疗中心有限公司 免疫抑制组合物及方法
IES20030305A2 (en) * 2002-04-23 2003-10-29 Desmond Joseph Fitzgerald Inhibition of platelet aggregation
DE602004029252D1 (de) * 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
ATE473016T1 (de) 2003-11-04 2010-07-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von krebs mit expression des cd40-antigens
GEP20105059B (en) 2004-07-26 2010-08-10 Biogen Idec Inc Anti-cd154 antibodies
WO2006017574A1 (en) * 2004-08-03 2006-02-16 Mayo Foundation For Medical Education And Research Improving treatments
ES2429564T3 (es) 2005-05-18 2013-11-15 Novartis Ag Procedimientos para el diagnóstico y tratamiento de enfermedades que tienen un componente autoinmune y/o inflamatorio
MX2008013508A (es) 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln

Also Published As

Publication number Publication date
HUP0002048A2 (hu) 2000-10-28
US20020119151A1 (en) 2002-08-29
IL133305A0 (en) 2001-04-30
KR20010013964A (ko) 2001-02-26
CN1651071A (zh) 2005-08-10
NZ502051A (en) 2001-04-27
EP1034001B1 (de) 2004-08-04
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
CZ458899A3 (cs) 2000-04-12
NO996274D0 (no) 1999-12-17
BG104092A (en) 2000-10-31
EP1034001A1 (de) 2000-09-13
AU733062B2 (en) 2001-05-03
CN1261285A (zh) 2000-07-26
ATE272408T1 (de) 2004-08-15
EA200000059A1 (ru) 2000-08-28
AU8153698A (en) 1999-01-04
KR100567998B1 (ko) 2006-04-07
PT1034001E (pt) 2004-12-31
WO1998058672A1 (en) 1998-12-30
CA2294138A1 (en) 1998-12-30
BG64436B1 (en) 2005-02-28
TR199903141T2 (xx) 2000-09-21
IS5274A (is) 1999-11-26
SK285962B6 (sk) 2007-12-06
ES2226152T3 (es) 2005-03-16
NO996274L (no) 2000-02-18
EA002512B1 (ru) 2002-06-27
BR9810755A (pt) 2000-08-15
IS2097B (is) 2006-04-12
JP2002504910A (ja) 2002-02-12
CZ295805B6 (cs) 2005-11-16
HK1031825A1 (en) 2001-06-29
SK180399A3 (en) 2000-06-12
DE69825473T2 (de) 2005-08-04

Similar Documents

Publication Publication Date Title
DE69825473D1 (de) Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine
SE9800836D0 (sv) New Compounds
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
NO884840D0 (no) Fremgangsmaate for behandling av underjordiske formasjoner med gelfluider som gir forsinket kryssbinding.
NO20016007L (no) Rekombinant anti-CD40-antistoff og anvendelser derav
ATE310011T1 (de) Inhibitoren des interleukin-1-beta konvertierenden enzyms
NO20005265L (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
ATE170868T1 (de) Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
IS5247A (is) Notkun CD40:CD154 bindingarrofa til að koma í vegfyrir ónæmissvörun gegn aðlögun, einkum höfnun græðlinga
PT966465E (pt) Inibidores do enzima imfdh
DE69840603D1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
BR9811099A (pt) Inibidores de urocinase
DK641589A (da) N-aryl-azetidinoner, fremgangsmaade til deres fremstilling og deres anvendelse som elastaseinhibitorer
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
ATE213937T1 (de) Spezielle halofantrinhaltige zusammensetzungen
ATE258789T1 (de) 5-ht2-antagonisten in der behandlung venöser zustände
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
WO1998018818A3 (en) Hepatitis b inhibitors
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
DK0434020T3 (da) 2,19-Methylenoxy- og 2,19-methylenthiobroforbundne steroider og deres anvendelse som inhibitorer af aromatase og 19-hydroxylase
MX9704579A (es) Composicion farmaceutica que comprende mirtazapina y uno o mas inhibidores selectivos de reabsorcion de serotonina.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee